Journals / Medeniyet Medical Journal / 2020 / Cilt: 35 - Sayı: 2

Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer

Lokal İlerlemiş Prostat Kanseri için Noninvaziv Diyagnostik Bir Biyobelirteç Olarak Sapmış SOCS3 Promotör Metilasyonu

Pages
99–105
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localizedPCa (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT),Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, bloodbased epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa).Method: A total of 41 consecutive patients and 10 healthy control groups were enrolled in thestudy.
📊
Key Findings & Data:Pyrosequencing was performed to analyze the methylation levels of the promoter regionsof the four tumor suppressor genes in patients compared to healthy controls.Results: The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differbetween the patient and control groups.
💡
Conclusion & Impact:However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localizedPCa (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to investigate the promoter methylation status of Rasassociated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT),Phosphatase with tensin homology (PTEN) and Suppressor of cytokine signaling 3 (SOCS3) tumor suppressor genes and evaluate the clinical utility of these genes as noninvasive, bloodbased epigenetic biomarkers for the diagnosis of Prostate Cancer (PCa).Method: A total of 41 consecutive patients and 10 healthy control groups were enrolled in thestudy. Pyrosequencing was performed to analyze the methylation levels of the promoter regionsof the four tumor suppressor genes in patients compared to healthy controls.Results: The promoter methylation levels of RASSF1A, MGMT, PTEN and SOCS3 did not differbetween the patient and control groups. However, SOCS3 promoter methylation level was significantly higher for patients having locally advanced PCa compared to those having localizedPCa (p

Özet

Amaç: Bu çalışmanın amacı tümör baskılayıcı genler Ras-associated domain family 1A (RASSF1A), O-6-methylguanine-DNA methyltransferase (MGMT), Phosphatase with tensin homology (PTEN) ve Suppressor of cytokine signaling 3 (SOCS3)’in promotör metilasyonlarını araştırmak ve bu genlerin Prostat Kanseri (PK) tanısı için noninvaziv, kan temelli epigenetik biyobelirteçler olarak klinik yararını değerlendirmekti. Yöntem: 41 hasta ve 10 sağlıklı kontrol grubu çalışmaya kaydedildi. Dört tümör baskılayıcı genin promotör bölgelerinin metilasyon düzeylerini hastalarda sağlıklı kontrol grubuna kıyasla analiz etmek için pirodizileme gerçekleştirildi. Bulgular: RASSF1A, MGMT, PTEN ve SOCS3 promotör metilasyon düzeyleri hasta ve konrol grubu arasında farklı değildi. Ancak SOCS3 promotör metilasyon düzeyi lokalize PK’lı hastalara kıyasla lokal olarak ilerlemiş PK’lı hastalarda önemli şekilde daha yüksekti (p

🔖

Cite This Article

YILDIRIM, A., TURAN, T., TAN, B. D., YUCEL, B., KARA, S. A., YILMAZ, S. S. (2022). Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer. Medeniyet Medical Journal, Cilt: 35 - Sayı: 2, 99–105. https://ajindex.com/articles/579242

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence. Front Oncol. 2019
  2. [CrossRef] 2. Wu Y, Davison J, Qu X, et al. Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer. Epigenetics.2016
  3. [CrossRef] 3. Martin NE. New developments in prostate cancer biomarkers. Curr Opin Oncol. 2016
  4. [CrossRef] 4. Eifler JB, Feng Z, Lin BM, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013
  5. [CrossRef] 5. Moschini M, Spahn M, Mattei A, Cheville J, Karnes RJ. Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics. BMC Med. 2016
  6. [CrossRef] 6.Grogan J, Gupta R, Mahon KL, et al. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up. BJU Int. 2017
  7. [CrossRef] 7. Yegnasubramanian S, De Marzo AM, Nelson WG. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications. Cold Spring Harb Perspect Med. 2019
  8. pii:a030445. [CrossRef] 8. Brait M, Banerjee M, Maldonado L, et al. Promoter methylation of MCAM, ERa and ERb in serum of early stage prostate cancer patients. Oncotarget. 2017
  9. 15431-40. [CrossRef] 9. Luo JH, Ding Y, Chen R, et al. Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol. 2013
  10. [CrossRef] 10. Blute ML Jr, Damaschke NA, Jarrard DF. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. Curr Opin Urol. 2015
  11. [CrossRef] 11. Mahon KL, Qu W, Lin HM, et al. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. Eur Urol. 2018
  12. pii: S0302-2838(18)30855-8. [CrossRef] 12. Martignano F, Gurioli G, Salvi S, et al. GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Dis Markers. 2016
  13. 4358292. [CrossRef] 13. Kim YJ, Yoon HY, Kim SK, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res. 2011
  14. [CrossRef] 14. Moreira-Bar